Effect of sex and low flow after surgical or transcatheter aortic valve replacement: an analysis of partner 2 and 3 trials
Document Type
Conference Proceeding
Publication Date
3-2022
Publication Title
Journal of the American College of Cardiology
Abstract
Background: Low flow (LF), defined as stroke volume index (SVi) ≤35 ml/m2, following transcatheter or surgical aortic valve replacement (TAVR or SAVR) in patients with severe aortic stenosis (AS) is associated with adverse outcomes. Sex-specific thresholds for LF (i.e., SVi ≤35 ml/m2 in women and SVi ≤40 ml/m2 in men) may better stratify risk.
Methods: Patients from the PARTNER 2 and 3 trials were stratified by sex and treatment arm. Those with LF were identified using both the standard and sex-specific definitions. The composite rate of death or heart failure hospitalization (HFH) two years post-intervention was compared between groups.
Results: Of the 1,717 men and 1,044 women available for analysis, LF was more common in men than women, by both the standard (37.3% vs. 30.2%; p=0.001) and sex-specific (60.2% vs. 19.4%; p< 0.001) thresholds. Compared to the standard threshold, sex-specific LF thresholds better stratified risk of the composite endpoint, especially in women (log-rank p=0.004 vs. 0.04). LF defined by sex-specific (Figure) or standard thresholds was predictive of the composite endpoint in men after TAVR (both p=0.004) and SAVR (p=0.08 or p=0.01) and in women only after SAVR (p=0.008 or p=0.02). Analyses focused on death alone had similar results.
Conclusion:Sex-specific thresholds for LF may better stratify risk of death or HFH after AVR for AS, compared to a standard threshold for both sexes. In women with LF, TAVR may improve outcomes compared to SAVR. Further study is needed.
Volume
79
Issue
9 Supplement
First Page
717
Recommended Citation
Clavel MA, Hahn RT, Abbas AE, Daubert MA, Douglas PS, Elmariah S, Zhao Y, Mack MJ, Leon MB, Pibarot P. Effect of sex and low flow after surgical or transcatheter aortic valve replacement: an analysis of partner 2 and 3 trialsJournal of the American College of Cardiology. 2022 Mar 8;79(9_Supplement):717-.